Last edition
News about "ozureprubart"
GSK completes acquisition of RAPT Therapeutics
GSK has completed the acquisition of RAPT Therapeutics, adding ozureprubart, a long-acting anti-IgE monoclonal antibody, to its pipeline. The candidate is currently in phase-II(b) development for prophylactic protection against food allergens, strengthening GSK’s immunology portfolio.
Ozureprubart | 05/03/2026 | By Akanki
GSK will acquire RAPT Therapeutics for USD 2.2 billion, adding phase IIb anti-IgE antibody ozureprubart to its pipeline, targeting long-acting protection for patients with severe food allergies.
Ozureprubart | 20/01/2026 | By News Bureau | 167
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy